Beyond Air Logo
US08862L1035
A2PNGL
XAIR

Beyond Air

Loading quotes...

Forecast

The analysts' average price target is +0,86 (78,61%). The median is +0,86 (78,61%).

Buy
  6
Hold
  1
Sell
  0

  • Beyond Air sells 58% NeuroNOS stake to Univo and receives share package

    Beyond Air sells its approximately 58% stake in NeuroNOS to Univo and receives common shares equal to 19.99% of Univo, plus warrants for an additional 19.99% (exercise price $0.01; term five years). Certain IP and development assets of NeuroNOS will be transferred to NeuroNOS. Beyond Air is entitled to development milestones of up to $6.5 million and commercial milestones of up to $26.0 million. The transaction is subject to regulatory, exchange- and consent-related approvals and other customary closing conditions. » More on de.investing.com


  • Beyond Air meets Nasdaq requirements after 1:20 reverse split

    Beyond Air announced that a 1:20 reverse stock split brought its minimum bid price to at least $1.00; the stock recorded 17 trading days with closing prices of at least $1.00 from July 13 to August 4 and therefore remains listed on Nasdaq, but is subject to a one-year monitoring period. The company reported fiscal 2026 revenue rising to $7.7 million and a positive gross profit of $300,000, while net loss narrowed to $33.2 million ($4.01 per share). The stock last traded at $5.56, is down roughly 90% from a year earlier, and has a market capitalization of about $4.08 million; in pre-market trading it fell about 9.85%. » More on de.investing.com


  • Beyond Air reports significantly smaller annual loss and strong revenue growth

    Beyond Air released quarterly figures for the period ending 31 March 2026: EPS was -0.77 USD for the quarter (previous year -1.80 USD) with revenue of 1.9 million USD (+66.09%). For the fiscal year the company reports EPS of -4.01 USD versus -13.80 USD in the prior year, and annual revenue rose to 7.68 million USD (+107.01%). » More on finanzen.net

Financials

In the last quarter, Beyond Air had revenue of +1,55 Mio and net profit of 6,95 Mio
(EUR) Jun 2026
YoY
Revenue +1,55 Mio 3,74%
Gross profit +197,15k 48,95%
Net profit 6,95 Mio 6,55%
EBITDA 5,66 Mio 1,01%

Fundamentals

Metric Value
Market capitalization
+3,04 Mio
Number of shares
720,53k
52-week high/low
+82,09 - +3,76
Dividends No
Beta
0,15
P/E ratio
0,09
PEG ratio
0,00
P/B ratio
+1,77
P/S ratio
+0,46

Company profile

Beyond Air, Inc. ist ein Medizintechnik- und Biopharmaunternehmen im klinischen Stadium, das Stickstoffmonoxid (NO)-Generatoren und -Verabreichungssysteme entwickelt. Das Unternehmen entwickelt das LungFit-System, ein NO-Generator- und Verabreichungssystem, das sich in der klinischen Erprobung für die Behandlung von persistierendem Lungenhochdruck bei Neugeborenen, akuter viraler Lungenentzündung, einschließlich COVID-19, Bronchiolitis und nichttuberkulösen Mykobakterien-Lungeninfektionen sowie soliden Tumoren befindet. Es ist in Israel, Irland, Australien und der Europäischen Union tätig. Das Unternehmen war früher als AIT Therapeutics, Inc. bekannt und änderte im Juni 2019 seinen Namen in Beyond Air, Inc. Der Sitz von Beyond Air, Inc. befindet sich in Garden City, New York.

Name
Beyond Air
CEO
Robert Goodman
Headquarters Garden City, ny
USA
Website
Sector
Consumer Discretionary
Industry
Household Durables
IPO
06/12/2018
Employees 54

Ticker symbols

Exchange Symbol
NASDAQ
XAIR
Frankfurt
48L.F
Düsseldorf
48L.DU
München
48L.MU
🍪

Parqet  uses cookies. Learn more